WO2009031671A1 - p53の発現促進方法およびそれに用いるp53発現促進剤 - Google Patents
p53の発現促進方法およびそれに用いるp53発現促進剤 Download PDFInfo
- Publication number
- WO2009031671A1 WO2009031671A1 PCT/JP2008/066127 JP2008066127W WO2009031671A1 WO 2009031671 A1 WO2009031671 A1 WO 2009031671A1 JP 2008066127 W JP2008066127 W JP 2008066127W WO 2009031671 A1 WO2009031671 A1 WO 2009031671A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- expression
- gene
- transcribed
- exon
- vegf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/676,443 US20100197765A1 (en) | 2007-09-07 | 2008-09-05 | Method for promoting the expression of p53, and p53 expression promoter for use in the method |
EP08829249A EP2198891A4 (en) | 2007-09-07 | 2008-09-05 | METHOD OF PROMOTING EXPRESSION OF P53 AND P53 EXPRESSION PROMOTERS FOR USE IN THE METHOD |
CN200880106106.2A CN101795714B (zh) | 2007-09-07 | 2008-09-05 | p53的表达促进方法和该方法中使用的p53表达促进剂 |
JP2009531301A JP5273740B2 (ja) | 2007-09-07 | 2008-09-05 | p53の発現促進方法およびそれに用いるp53発現促進剤 |
CA2697737A CA2697737A1 (en) | 2007-09-07 | 2008-09-05 | Method for promoting expression of p53, and p53 expression promoter for use in the method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007233316 | 2007-09-07 | ||
JP2007-233316 | 2007-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009031671A1 true WO2009031671A1 (ja) | 2009-03-12 |
Family
ID=40428983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/066127 WO2009031671A1 (ja) | 2007-09-07 | 2008-09-05 | p53の発現促進方法およびそれに用いるp53発現促進剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20100197765A1 (ja) |
EP (1) | EP2198891A4 (ja) |
JP (1) | JP5273740B2 (ja) |
CN (1) | CN101795714B (ja) |
CA (1) | CA2697737A1 (ja) |
WO (1) | WO2009031671A1 (ja) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1252308A2 (en) * | 2000-01-19 | 2002-10-30 | Parkash S. Gill | Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides |
US20050054596A1 (en) * | 2001-11-30 | 2005-03-10 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
FR2832154B1 (fr) * | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
US8426194B2 (en) * | 2003-01-21 | 2013-04-23 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating VEGF expression |
CN100352922C (zh) * | 2003-08-07 | 2007-12-05 | 徐根兴 | 抑制人VEGF基因的表达的siRNA和表达载体及其在制药中的应用 |
AU2005222902B2 (en) * | 2004-03-12 | 2010-06-10 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
WO2006042328A2 (en) * | 2004-10-12 | 2006-04-20 | John Wayne Cancer Institute | Treatment of cancer and compositions |
KR20080041145A (ko) * | 2005-04-12 | 2008-05-09 | 인트라디그엠 코오포레이션 | 암 및 다른 신생혈관증식 질환을 치료하기 위한 RNAi치료제의 조성물 및 방법 |
CN100371444C (zh) * | 2005-12-12 | 2008-02-27 | 清华大学深圳研究生院 | 一种抑制VEGF表达的siRNA及其应用 |
-
2008
- 2008-09-05 CN CN200880106106.2A patent/CN101795714B/zh not_active Expired - Fee Related
- 2008-09-05 WO PCT/JP2008/066127 patent/WO2009031671A1/ja active Application Filing
- 2008-09-05 CA CA2697737A patent/CA2697737A1/en not_active Abandoned
- 2008-09-05 JP JP2009531301A patent/JP5273740B2/ja not_active Expired - Fee Related
- 2008-09-05 EP EP08829249A patent/EP2198891A4/en not_active Withdrawn
- 2008-09-05 US US12/676,443 patent/US20100197765A1/en not_active Abandoned
Non-Patent Citations (23)
Title |
---|
AKIRI, G. ET AL., ONCOGENE, vol. 17, 1998, pages 227 - 236 |
BIROCCIO, A. ET AL.: "The future of antisense therapy: combination with anticancer treatments", ONCOGENE, vol. 22, no. 42, 2003, pages 6579 - 88, XP008118435 * |
BORNES, S. ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 18717 - 18726 |
BUNZ, F. ET AL., J. CLIN. INVEST., vol. 104, 1999, pages 263 - 269 |
HASSAN, I. ET AL.: "Antisense p53 decreases production of VEGF in follicular thyroid cancer cells", ENDOCRINE, vol. 29, no. 3, 2006, pages 409 - 12, XP008132342 * |
HIRASHIMA; INOUE: "Idenshi no Fukusei to Hatsugen", 1993, JAPANESE BIOCHEMICAL SOCIETY, article "Shin Seikagaku Jikken Koza 2", pages: 319 - 347 |
HUEZ, 1. ET AL., MOL. CELL. BIOL., vol. 18, 1998, pages 6178 - 6190 |
HUEZ, I. ET AL., MOL. CELL. BIOL., vol. 18, 1998, pages 6178 - 6190 |
HUEZ, I. ET AL., MOL. ENDOCRINOL., vol. 15, 2001, pages 2197 - 2210 |
IM, S.A. ET AL.: "Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo", CANCER RES, vol. 59, no. 4, 1999, pages 895 - 900, XP008132334 * |
J. ABRAHAM ET AL., J. BIOL. CHEM., vol. 266, no. 18, 1991, pages 11947 - 11954 |
KAWANO, M. ET AL., NUCLEIC ACID RES., vol. 33, no. 3, 2005, pages 1040 - 1050 |
KONISHI, T. ET AL.: "The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 16, no. 3, 2000, pages 501 - 511, XP008132340 * |
LEVINE, A. ET AL., CELL, vol. 88, 1997, pages 323 - 331 |
MASUDA, K. ET AL., PLOS MED., vol. 5, 2008, pages E94 |
MASUDA, K. ET AL.: "A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA", PLOS MED, vol. 5, no. 5, 20 May 2008 (2008-05-20), pages e94, XP008132344 * |
MORINO, F. ET AL.: "Hammerhead ribozyme specifically inhibits vascular endothelial growth factor gene expression in a human hepatocellular carcinoma cell line", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 17, no. 3, 2000, pages 495 - 499, XP008132333 * |
PHAROAH, P. ET AL., BR. J. CANCER, vol. 80, 1999, pages 1968 - 1973 |
RAMAN, V. ET AL., NATURE, vol. 405, 2000, pages 974 - 978 |
See also references of EP2198891A4 |
STEELE, R. ET AL., BR. J. SURG., vol. 85, 1998, pages 1460 - 7 |
VOGELSTEIN, B. ET AL., NATURE, vol. 408, 2000, pages 307 - 310 |
YAMANAKA, K. ET AL.: "Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model", MOL CANCER THER, vol. 4, no. 2, 2005, pages 187 - 95, XP008132338 * |
Also Published As
Publication number | Publication date |
---|---|
CN101795714A (zh) | 2010-08-04 |
JPWO2009031671A1 (ja) | 2010-12-16 |
CN101795714B (zh) | 2014-05-14 |
EP2198891A1 (en) | 2010-06-23 |
JP5273740B2 (ja) | 2013-08-28 |
US20100197765A1 (en) | 2010-08-05 |
EP2198891A4 (en) | 2011-12-21 |
CA2697737A1 (en) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200908342B (en) | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA | |
EP1742958A4 (en) | METHODS AND COMPOSITIONS FOR SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE STRANDED RNA | |
WO2011133871A3 (en) | 5'-end derivatives | |
EP1986697A4 (en) | COMPOSITIONS AND METHODS FOR GENE SILENCING INHIBITION USING RNA INTERFERENCE | |
WO2014144592A3 (en) | Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing | |
WO2009076400A3 (en) | Compositions and methods for inhibiting expression of factor vii gene | |
WO2010033225A3 (en) | Compositions and methods for the specific inhibition of gene expression by dsrna | |
EP2431465A4 (en) | METHOD FOR SYNTHESIS OF DOUBLE-STRENGTHED DNA ACCORDING TO AN RNA AND METHOD FOR DNA AMPLIFICATION | |
WO2008121604A3 (en) | Compositions and methods for inhibiting expression of a gene from the ebola | |
WO2007093776A3 (en) | Nucleic acid | |
WO2007143086A3 (en) | Delivery method | |
WO2009039198A3 (en) | Generation of hyperstable mrnas | |
WO2012177947A3 (en) | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes | |
WO2012018881A3 (en) | Methods and compositions for the regulation of rna | |
WO2011005799A3 (en) | Rna containing modified nucleotides and use thereof in vaccines | |
WO2005118824A3 (en) | Methods and compositions for the inhibition of gene expression | |
WO2005112636A3 (en) | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF PRIMATE POLYOMAVIRUS GENES | |
WO2010045384A3 (en) | Short hairpin rnas for inhibition of gene expression | |
WO2011020023A3 (en) | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus | |
WO2009124137A3 (en) | Method of suppressing gene transcription through histone lysine methylation | |
WO2013003489A3 (en) | Method for genome complexity reduction and polymorphism detection | |
WO2008146251A3 (en) | A primary micro rna expression cassette | |
AU2007338403A1 (en) | shRNA-mediated inhibition of expression of alpha-1. 6-fucosyltransferase | |
WO2008030996A3 (en) | Sirna and methods of manufacture | |
WO2012027713A3 (en) | Compositions and methods for inhibition of snca |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880106106.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08829249 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009531301 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2697737 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12676443 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008829249 Country of ref document: EP |